4/13/2012

MAP Pharmaceuticals plans to request a meeting with the FDA about manufacturing issues that prompted a complete-response letter for inhaled migraine drug Levadex. MAP and marketing partner Allergan are working to address agency concerns, MAP President and CEO Timothy Nelson said.

Related Summaries